• OPEN AN ACCOUNT
Indian Indices
Sensex
72,945.06 -122.75
( -0.17%)
Global Indices
Nasdaq
51,551.76 262.86
(0.51%)
Dow Jones
7,841.47 46.52
(0.60%)
Hang Seng
70,716.70 769.84
(1.10%)
Nikkei 225
10,543.25 45.31
(0.43%)
Forex
USD-INR
96.27 0.31
(0.32%)
EUR-INR
107.88 -0.09
(-0.09%)
GBP-INR
127.24 0.23
(0.18%)
JPY-INR
0.61 0.00
(0.27%)

EQUITY - MARKET SCREENER

ICICI Prudential Nifty Alpha Low Volatility 30 ETF
Industry :  Stock Exchanges
BSE Code
ISIN Demat
Book Value()
543219
INF109KC17V7
1.3183596
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ALPL30IETF
0
1583.83
EPS(TTM)
Face Value()
Div & Yield %
0
1
0
 

Biocon's Malaysia units receives UK MHRA approval for Semglee fill finish unit
Sep 25,2026

In July, Biocon had secured regulatory approval from the European Medicines Agency (EMA) for this new drug product fill-finish line.

The announcement was made before market hours today, 25 September 2026.

Biocon is a Bengaluru-based biopharmaceutical company focused on biosimilars and generic medicines, with operations across more than 120 countries.

The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.

The scrip shed 0.58% to currently trade at Rs 384.75 on the BSE.